Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program, a public-private partnership to speed development of the most promising treatments and vaccine candidates. It also is receiving support through Operation Warp Speed, the U.S. government’s multi-agency effort to develop, manufacture and distribute medical countermeasures to fight COVID-19. Dr. Johnson is site principal investigator for ACTIV-3 with co-investigators Dr. Dan Henning and Dr. Bryce Robinson (Surgery).
ACTIV-3 is represents a pan-NIH and industry platform trial to test monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. ACTIV-3 will enroll hospitalized patients at Harborview Medical Center and other select hospitals around the world that are part of existing clinical trial networks, including International Network of Strategic Initiatives in Global HIV Trials (INSIGHT), operated by the National Institute of Allergy and Infectious Diseases (NIAID), Prevention and Early Treatment of Acute Lung Injury network (PETAL) and Cardiothoracic Surgical Trials Network (CTSN), and the U.S. Department of Veterans Affairs Medical Centers (https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-test-antibody-treatment-hospitalized-covid-19-patients).